본문 바로가기

Meet Us at 2025 ASCO GI Cancers Symposium

Meet Us at WORLD Symposium 2025

Meet Us at 2025 ASCO GI Cancers Symposium.

A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer
Poster Number
426
Session
Jan 23 at 11:30~1:00 PM, Poster Board #E16
Presenter
Do-Youn Oh, M.D., Ph.D. / Seoul National University Hospital,
Paul (DongJun) Rhee, Ph.D. / Hanmi Pharmaceutical

Meet Us at WORLD Symposium 2025.

Beneficial effects of HM15421, a novel long-acting alpha-galactosidase A analog, following a switch from the conventional enzyme replacement therapy in a symptomatic Fabry mouse model
Poster Number
LB-22
Session
Feb 4 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
Presenter
Cho Rong Park, Ph.D. /
Hanmi Pharmaceutical
A novel long-acting alpha-galactosidase A analog, HM15421, mitigates progressive renal impairment in Fabry disease via enhanced renal targeting and prolonged cellular retention
Poster Number
LB-41
Session
Feb 5 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
Presenter
Cho Rong Park, Ph.D. /
Hanmi Pharmaceutical
Comparative efficacy of conventional ERT drugs and HM15421, a novel long-acting alpha-galactosidase A analog, in a symptomatic Fabry mouse model
Poster Number
LB-24
Session
Feb 4 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
Presenter
Wonki Kim, Ph.D. / Hanmi Pharmaceutical

Hanmi's New Story

힘차게 도약하는 한미
함께하는 미래

한미약품의 새로운 이야기가 펼쳐집니다.

Focus on Making
Innovative Medicines

한미약품은 다양한 치료 영역을 포괄하는
탄탄한 R&D 인프라를 바탕으로
제약분야에서 혁신을 선도하고 있습니다.

비만/대사

비만, 대사 이상 관련 지방간염 등 다양한 작용기전
Best-in-class 신약 개발

View More

What We Make

ESG Report

한미약품의 ESG 경영은
'일상의 혁신'입니다.

View More

당신의 꿈이
한미약품의 미래입니다.
당신을 기다립니다.

Join Us